- 1 Harnessing methods, data analysis, and near-real-time wastewater monitoring for enhanced public
- 2 health response using high throughput sequencing.
- Padmini Ramachandran^{1*}, Tunc Kayikcioglu^{1,2}, Tamara Walsky¹, Kathryn Judy¹, Jasmine Amirzadegan¹, 3
- Candace Hope Bias¹, Bereket Tesfaldet¹, Maria Balkey, Dietrich EppSchmidt^{1,2}, Hugh Rand¹, James 4
- Pettengill¹, Sandra Tallent¹, Eric Brown¹, Tina Pfefer¹, Ruth Timme¹, Amanda Windsor¹, Christopher 5
- Grim¹, and Maria Hoffmann¹ 6
- 7 1. Center for Food Safety and Applied Nutrition, Food and Drug Administration, Office of
- 8 Regulatory Science, Division of Microbiology, HFS-712, 5001 Campus Drive, College Park, MD
- 9 20740, USA.
- 2. Joint Institute for Food Safety and Applied Nutrition, University of Maryland, 5825, University 10
- 11 Research Ct, Suite 1400, College Park, MD, USA.
- 12
- Address correspondence to: 13
- 14 Padmini Ramachandran
- 15 5001, Campus Drive, 4E-019,
- 16 College Park, MD- 20740.
- 17 Ph no: 3017960610
- 18 Email: Padmini.ramachandran@fda.hhs.gov
- 19
- 20
- 21
- 22
- 23
- 24

25 Abstract

26 Wastewater-based analysis has emerged as a pivotal method for monitoring SARS-CoV-2 (SC2). 27 Leveraging high-throughput sequencing on wastewater samples facilitates a comprehensive, population-28 level assessment of circulating and emerging SC2 variants within a community. This study meticulously 29 evaluates the detection performance, variant calling accuracy, and the time taken from sample 30 collection to public data release for wastewater SC2 monitoring. We employed two different SC2 target 31 enrichment panels on Illumina MiSeq and Oxford Nanopore Technologies (ONT) GridION sequencing 32 platforms for a robust analysis. Daily collection of routine raw grab and composite samples took place at 33 a wastewater treatment plant (WWTP) site in Maryland, USA (MD) from mid-January 2022 to the end of 34 June 2022. Total Nucleic Acid (TNA) was extracted from samples and target enrichment was executed 35 using QIAseq DIRECT and NEBNext VarSkip Short amplicon kits, with subsequent sequencing on MiSeq 36 or ONT GridION platforms, respectively. Obtained sequences was analyzed using our custom CFSAN 37 Wastewater Analysis Pipeline (C-WAP). Raw sequence data and detailed metadata were submitted to 38 NCBI (BioProject PRJNA757291) as it became available. Our wastewater data successfully detected the 39 onset of new variants BA.2, BA.2.12, BA.4.6, and BA.5 to the observed population. Notably, Omicron 40 sub-variants were identified approximately a week ahead of publicly available clinical data at the MD 41 ZIP-code level. Variation in quality metrics paralleled the rise and fall of BA waves, underscoring the 42 impact of viral load on sequencing quality. Regular updates of estimated variant proportions were made 43 available on the FDA-CFSAN "Wastewater Surveillance for SARS-CoV-2 Variants" website. In contrast to 44 the median 28-day turnaround for our samples, the lead time from sample collection to public release of 45 raw sequence data via NCBI was remarkably swift, accomplished within a mere 57 hours in this specific 46 exercise. Our processing, sequencing, and analysis methods empowered the swift and accurate 47 detection of SC2 trends and circulating variants within a community, offering insights for public health 48 decision-making.

49 Keywords

50 Wastewater, surveillance, SARS-CoV-2, sequencing

51 Abbreviations

- 52 SARS-CoV-2 (SC2), Wastewater treatment plant (WWTP), Total Nucleic Acid (TNA), CFSAN Wastewater
- 53 Analysis Pipeline (C-WAP).

68 Introduction

69	Clinical variant determination of SARS-CoV-2 (SC2) relies on the detection of genomic elements
70	of SARS-CoV-2 by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) based
71	methods from individual patients (1, 2). Clinical analyses are now also being complemented with
72	antibody-based assays that provide an indication of current or previous exposure to SC2 (3). High-
73	throughput sequencing technologies are being used to sequence the SC2 genome from a subset of the
74	infected population (4, 5). This has resulted in a large number of published genomes, and has provided
75	insight into its origins, spread, evolution, and diversity via computational approaches in genomic
76	epidemiology (1). However, inferring lineage prevalence by clinical testing is infeasible at scale,
77	especially in areas with limited testing and/or sequencing capacity or limited community participation,
78	both of which can introduce sampling biases (4).
79	Utilizing wastewater samples to identify pathogenic human viruses, including SC2, has gained
80	attention as a method for understanding population-level trends in infections (3). SARS-CoV-2 RNA
81	concentration in wastewater has been shown to convey regional infection dynamics and provides less
82	biased abundance estimates than clinical testing (1, 3). As SC2 continues to spread and evolve, early
83	detection of emerging variants is critical for orchestrating public health interventions.
84	There are many factors limiting wastewater-based genomic surveillance of pathogens. For
85	example, despite the promising success of a few studies (6, 7), it is still challenging to understand how
86	well wastewater-based epidemiology can identify the genetic diversity of SARS-CoV-2 in each population
87	and how this relates to known viral diversity of clinical cases. This is especially important as new variants
88	emerge (1). Many challenges also lie in the accurate identification of SC2 variants and estimation of their
89	abundance in mixed population samples such as wastewater. While deep sequencing without prior

90 amplification may be efficient for viruses that reside in high quantity in plasma, in a mixed population of

91 variants and a complex environmental matrix like wastewater, sequencing without amplification is 92 impractical (8). For wastewater-based viral detection, implementation of a multiplexed target 93 enrichment panel is necessary. However, there are challenges in the analysis of sequencing reads from 94 target enrichment panels for accurate identification of multiple variants in a single sample. Here we use 95 an analysis pipeline, the CFSAN Wastewater Analysis Pipeline (C-WAP, https://github.com/CFSAN-96 Biostatistics/C-WAP), for identification and abundance estimation of circulating variants. As SC2 evolves 97 and new variants arise, continued monitoring for emerging variants will be an important component of 98 public health efforts (9). As the virus evolves, enrichment kits, databases of variants, and detection 99 methods will also need to evolve and be re-evaluated to ensure the best possible methods are in use. 100 The application of high-throughput sequencing for the rapid identification and surveillance of 101 pathogens has recently become common place in public health systems (10-12). The SC2 pandemic has 102 helped bring WBE to the forefront of community-scale pathogen surveillance (7, 13). Here, we describe 103 how monitoring wastewater from urban areas can be used to detect the arrival of emerging SC2 variants 104 of SC2 in a chosen sewer shed. This study adapted two different target enrichment panels, initially 105 designed for clinical samples, for application in wastewater samples. Additionally, both protocols were optimized and published to protocols.io (14). The study established critical quality control checkpoints 106 107 within the laboratory workflow and on the analysis of sequence data derived from a mixed population of 108 wastewater samples. The evaluation encompassed the detection performance and variant calling 109 accuracy using two different SC2 target enrichment panels, covering 99.16 +/- 0.58% of the SC2 genome 110 conducted on both Illumina MiSeg and Oxford Nanopore Technologies (ONT) GridION sequencing 111 platforms. A crucial aspect explored was the turn-around-time from sample collection to public data 112 release, recognizing its significant public health impact. The findings demonstrated the effectiveness of 113 high-throughput sequencing of SC2 genomes from wastewater. The incorporation of precision analysis

tools, such as C-WAP, facilitated the early detection of emerging variants of concern in wastewatersamples.

116	In summary, this study emphasizes the need for community-based surveillance, complemented
117	by rigorous and comprehensive analysis and investigation. The thorough analysis when assessing the
118	performance of enrichment panels employed here, considering the interplay between the enrichment
119	panel itself and the specific sequencing technology, is extremely valuable. This study utilized a
120	comprehensive wastewater analysis pipeline, crafted for real-time surveillance of mixed population
121	samples that took into consideration several aspects of targeted amplicon-based sequencing,
122	implemented strict QC measures to avoid false positives, critically assessed emerging variants by looking
123	at the characteristic mutations, and evaluated several genome coverage metrics across the genome. The
124	insights gained from this study offer valuable lessons applicable to wastewater surveillance
125	methodologies targeting emerging pathogens.
126	Materials and Methods
127	Sample collection
128	Wastewater samples were collected from a wastewater treatment plant in Maryland from
129	January 12, 2022, to June 28 th , 2022. The raw wastewater was collected daily from January 12 th to
130	February 28 th , 2022 as two 1-liter raw grabs (2 biological reps) in Nalgene bottles and stored at 4°C. The
131	samples were retrieved weekly and subsequently stored at 4°C until use. From January 12 to February
132	28th, 2022, raw wastewater grab samples were extracted and analyzed as individual samples with 2
133	biological replicates for each day resulting in 14 samples per week.
134	Composites were collected as 1L grabs from Feb23 rd 2022 till June 28 th , 2022. Composites were
135	aliquoted from the auto sampler (auto sampler has a collection interval of 30 mins for 24hrs) as two-1L

136 grabs in Nalgene bottles and stored at 4°C until use. Each biological replicate per week after pooling was

- then split into three 40mL technical replicates, resulting in six samples per week (Supplementary table 1,
- 138 Schematic Fig 1). The complete workflow for this study is described in detail in Fig1.

139 Total nucleic acid extraction and SARS-CoV-2 RT-qPCR detection

- 140 Sample concentration and total nucleic acid extraction was performed on the pooled
- 141 wastewater using Maxwell RSC Enviro TNA Kit (Promega, Madison, WI USA) following manufacturer's
- 142 recommendations. The extracted total nucleic acid was stored at -20 C for short term (a week) to
- process for the cDNA generation and RT-qPCR. After the necessary amount was aliquoted, the TNA was
- stored at -80 C for long term storage. The detailed protocol has been published in
- 145 <u>dx.doi.org/10.17504/protocols.io.rm7vzy52xlx1/v1</u>.
- 146 The quantification of SARS-CoV-2 in wastewater was performed utilizing the Promega GoTaq®
- 147 Enviro Wastewater SARS-CoV-2 System, which targets the N1 gene (Promega, Madison, WI USA)
- 148 following manufacturer's recommendations. This includes guidance for converting RT-qPCR output into
- 149 calculated viral genome copies per liter.

150 **DNA digestion and cDNA synthesis**

- 151 Genomic DNA was digested with ezDNase (Invitrogen, Waltham, MA USA) with protocol
- modifications. Reaction cocktails consisted of 10uL template TNA, 2µL nuclease free water, 1µL
- 153 ezDNase[™] buffer, and 1 μL ezDNase[™] enzyme. Reactions were then digested at 37°C for 5 minutes.
- 154 Digestion was stopped by addition of 1µL 10mM DTT and a 5-minute incubation at 55°C. Reactions were
- 155 chilled on ice for at least 1 minute before proceeding to cDNA synthesis.
- 156 cDNA was synthesized from the purified RNA with the Superscript IV Reverse Transcriptase
- 157 (Invitrogen, Waltham, MA, USA) with modifications to the manufacturer protocol. Primer annealing was
- 158 carried out with 1µL 50µM random hexamers, 1uL 10mM dNTP mix, 1µL DEPC-treated water, and 10µL

template RNA. Reactions were incubated at 65°C for 5 minutes, then incubated on ice for at least 1
minute. The Reverse Transcriptase reaction mix was prepared with 4µL 5x SSIV Buffer, 1 µL 100mM DTT,
1µL RNaseOUT[™] Recombinant RNase Inhibitor, and 1µL SuperScript IV Reverse Transcriptase (200U/µL)
and then added to the chilled primer-annealed RNA. Reactions were then incubated at 23°C for 10
minutes, 50°C for 30 minutes, then 80°C for 10 min. cDNA was stored at -20°C until use.

164 Selection of enrichment panels for this study.

165 October through December 2021, we evaluated some commercially available SC2 enrichment 166 panels. Enrichment panels for assessment were chosen based on multiple criteria. Our main objective 167 was to ensure even coverage across the genome; therefore, we chose kits with tiled amplicon across the 168 entire SC2 genome and simple library preparation of these amplicons to achieve rapid, simple, and cost-169 effective sequencing. Read lengths of the amplicon to adapt to both short read sequencing chemistry 170 and long read sequencing chemistry were also considered. The commercial enrichment panels that were 171 assessed initially included Midnight FREED primers (1200 bp long amplicons with Oxford Nanopore 172 library and sequencing) (15), SWIFT SNAP additional genome coverage panel (150 bp long amplicons 173 with Illumina MiSeq sequencing) (16), NEBNext VarSkip Short primers (560 bp long, with possibility of 174 sequencing in both Illumina and ONT platform) (17), and QIAseg DIRECT enrichment panel (250 bp 175 amplicons with Illumina MiSeg sequencing). Based on the ease of generating the amplicons, ease of 176 library preparation and adaptability of the amplicons with different sequencing platforms we chose two 177 enrichment panels for this study that are discussed in detail in this manuscript, QIAseq DIRECT and 178 NEBNext VarSkip Short (NEB VSS). The QIAseq DIRECT panel has 222 primer pairs with average amplicon 179 length of 250 bp while the NEB VSS panel has 74 primer pairs with an amplicon length of about 560 bp, 180 on average.

- 181 QIAsed
 - QIAseq DIRECT SARS-CoV-2 enrichment panel

- 182 cDNA amplification was performed using QIAseq DIRECT SARS-CoV-2 enrichment panel
- 183 following manufacturer's protocols. After the emergence of variant BA.5, (June 13th, 2022), the
- 184 manufacturer distributed an auxiliary primer set as a spike-in to the existing protocol. The samples from
- 185 May 17th and onward were amplified using the spike-in to the enrichment panel. The detailed protocol
- 186 is publicly available at dx.doi.org/10.17504/protocols.io.rm7vzy39rlx1/v4
- 187 NEB VSS SARS-CoV-2 enrichment panel
- 188 cDNA amplification was performed utilizing the NEB VSS SARS-CoV-2 enrichment panel following
- 189 manufacturer's protocol. Due to the emergence of BA.2.12, there was a change in the primer version
- 190 from VSS v1a to VSS v2a starting from the week of March 1st. There was also a spike-in introduced in
- 191 the primer pairs as an update to the kit due to the emergence of BA.5. The samples from the week of
- 192 May 11th and onward were amplified using the enrichment panel with spike-in. The detailed protocol is

193 publicly available at dx.doi.org/10.17504/protocols.io.3byl4bwervo5/v2

- 194 High throughput Sequencing
- 195 QlAseq DIRECT amplicons were sequenced using Illumina MiSeq (Illumina, San Diego, CA). NEB
- 196 VSS amplicons were sequenced using Oxford Nanopore GridION sequencing (Oxford Nanopore
- 197 Technologies, Oxford, UK). Every sample (n = 182) was amplified using both QIAseq DIRECT SARS-CoV-2
- 198 enrichment panel and NEB VSS SARS-CoV-2 panel (n=364). The libraries of NEB VSS amplicons were
- 199 prepared using ligation sequencing kit (Oxford Nanopore Technologies Ligation Sequencing Kit (SQK-
- LSK109), Cambridge, UK) as described in the publicly available protocol
- 201 dx.doi.org/10.17504/protocols.io.3byl4bwervo5/v2 run on a R.9.4 flow cell (R9.4.1) for 72[®]h.
- 202 Data analysis, quality metrics and variant calling

203	To address the many challenges in accurate identification of multiple variants, we further
204	customized our analysis tool CFSAN Wastewater Analysis Pipeline (C-WAP)(9) . The latest version of C-
205	WAP is now available on GitHub <u>https://github.com/CFSAN-Biostatistics/C-WAP</u> . Briefly, sequences are
206	aligned to the reference genome (Wuhan-Hu-1, NCBI assembly ASM985889v3, NC_045512.2) using
207	Bowtie2 (v2.4.5) and Minimap2 (v2.24), followed by adapter trimming and quality filtering in iVar
208	(v1.3.1). When processing Illumina data, the iVar trim function was configured to discard the adaptor
209	sequences; filter sequences below a quality score of 20 (default); filter reads that are shorter than 50%
210	of the average length of the first 1000 reads (default); and use a 4 bp sliding window (default). For ONT
211	data, iVar trimming is configured the same, with the exception that all sequences are retained (quality
212	score filter of 1), effectively preserving the filtering of reads to a quality score of 7 performed by Guppy,
213	the default intrinsic base caller onboard ONT MinKNOW sequencing software.
214	C-WAP provides three methods for variant calling: Kraken2 (v2.1.2) / bracken (v2.7), kallisto
215	(v0.48), and a Samtools (v1.15) pileup piped into Freyja (v1.4.4). Bracken is a Bayesian abundance
216	estimator based on Kraken2 sequence calls. A comprehensive list of dependencies for C-WAP is available
217	in the GitHub readme.

218 C-WAP takes into account the number of raw reads that align to the reference sequence and 219 pass filter, *i.e.*, read lengths after adaptor trimming \geq 30 and minimum read quality \geq 20 within a sliding 220 window of width 4 bases. C-WAP outputs a comprehensive report along with several distinct quality 221 metrics (Table 1). These include the percent of reads aligned to SARS-CoV-2 genome, coverage depth of 222 the sequencing reads at every genomic coordinate of the SARS-CoV-2 genome, read quality, coverage 223 depth over the entire breadth of the SARS-CoV-2 genome, absolute counts of genomic coordinates with 224 less than 10X coverage or no coverage, scaled counts of genomic coordinates that with less than 10X 225 coverage or no coverage, and variant abundance estimation using Freyja, kallisto, and Kraken.

226	Characteristic mutations for several variants, including variants B.1.617.2, BA.1, BA.2, BA.3,
227	BA.4, and BA.5 (18), the variants of concern most relevant to the timeframe of this study, were
228	extracted from the C-WAP report (Supplementary table 2). The table is generated under the assumption
229	that the presence of a variant requires the detection of all mutations of a particular variant. The
230	characteristic mutations which support the presence of a particular variant are indicated in the
231	respective column of the table. A detected mutation table with detection frequency and p-values for
232	every alternate base in each position is generated where only the genomic coordinates with at least 10X
233	coverage were considered.
234	Concordance correlation coefficient
235	A concordance correlation coefficient (CCC) with Euclidean distance was used to evaluate the
236	levels of pairwise agreement among the abundance estimation methods for both amplicon panels, NEB
237	VSS and QIAseq DIRECT. It was adapted by Cui et al. (19) from Lin's concordance correlation coefficient
238	for agreement studies with microbiome compositional data. CCC has values between -1 and 1, where -1
239	indicates a perfect disagreement, 1 indicates a perfect agreement, and 0 indicates a complete absence
240	of agreement between the two abundance estimation methods. Bayes-Laplace Bayesian-multiplicative
241	replacement method (20) is used to impute zero relative abundances on the entire dataset before
242	computing CCC values. A bootstrap method with sample size of 5,000 is used to build a 95% confidence
243	interval for each CCC estimate.
244	To understand the agreement between the variant callers on real world data, in the amplicon
245	panels used in this study, for the CCC analysis a subset of (n= 11) samples were chosen. The sample
246	chosen for this analysis were samples collected on the week of May 5 th , 2022 (6 samples) and the week
247	of June 28 th , 2022 (5 samples). The 11 samples/22 sequences (with each sample being amplified with
248	NEB VSS and QIAseq DIRECT and sequenced in ONT and Illumina MiSeq respectively) were chosen based

249	on sequence reads having uniform coverage across the genome, good breadth versus depth metric and
250	higher percent covid hits. For the week of May 5th samples, the amplicon panels lacked the spike-in
251	primers. In this instance, the basic panel successfully identified the circulating variants at the time. For
252	the June 28th samples, both amplicon panels were equipped with updated spike-in primers capable of
253	detecting the prevailing variant circulating at that time.
254	Dashboard display
255	Sequencing data that passed QC assessment (category A and B, Table 1) were submitted in real
256	time to National Center for Biotechnology Information (NCBI) for active monitoring for circulating
257	variants. To facilitate the sharing of information about progress on this sequencing effort, FDA
258	developed a dashboard that graphically presented findings from this project (21). Active support and
259	updates to the dashboard ended on June 30, 2023, the final state of the dashboard remains available at
260	https://www.fda.gov/food/whole-genome-sequencing-wgs-program/wastewater-surveillance-sars-cov-
261	<u>2-variants.</u>
262	Data visualization:
263	Downstream data analysis and visualization were carried out in RStudio (v.1.3.1093) using the
264	following R packages: ggplot2 (v3.4.1), dplyr (v1.1.0), reshape2 (1.4.4), ggh4x, and stringr (v1.5.0).
265	Data availability:
266	Data generated in this study were deposited in the NCBI BioProject database under the
267	BioProject accession number PRJNA757291.
268	Results
269	SARS-CoV-2 viral load and relationship to clinical cases:

270	The viral load of SARS-CoV-2 in wastewater was assessed throughout the time course of this
271	study to understand the impact of viral burden levels and dynamics on amplicon sequencing success and
272	output. Computed viral load, calculated from RT-qPCR on samples taken from the wastewater
273	treatment plant, ranged from 350 genome copies/L to 99,840 genome copies/L, with fluctuations that
274	mirrored variant waves (Fig 2). To understand the relationship of wastewater-based surveillance burden
275	estimations and actual clinical reporting, clinical data were plotted against the viral genome copies/L
276	over time (Fig 2, Supplementary table 3). The rolling 7-day average of new clinical SARS-CoV-2 cases for
277	the two ZIP codes (21157 and 21158) served by the wastewater treatment plant was extracted from MD
278	department of Health website, <u>https://opendata.maryland.gov/Health-and-Human-Services/MD-COVID-</u>
279	<u>19-Cases-by-ZIP-Code/ntd2-dqpx/data_preview</u> . When compared to the reported clinical cases, which
280	ranged anywhere between 1 case per week to 866 cases per week, we observed a seemingly lower rate
201	of alinical tasting from March 2022 anward (Fig.2)
281	or childen testing from March 2022 onward (Fig 2).
281	Percent reads aligned vs genome copies of SARS-CoV-2
281 282 283	Percent reads aligned vs genome copies of SARS-CoV-2 Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364)
281 282 283 284	Percent reads aligned vs genome copies of SARS-CoV-2 Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364) were compared against the weekly average SC2 genome copies per liter of wastewater detected by RT-
281 282 283 284 285	Percent reads aligned vs genome copies of SARS-CoV-2 Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364) were compared against the weekly average SC2 genome copies per liter of wastewater detected by RT- qPCR (Fig 3). The average percent reads aligned to the SARS-CoV-2 genome from weekly sampling
281 282 283 284 285 286	Percent reads aligned vs genome copies of SARS-CoV-2 Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364) were compared against the weekly average SC2 genome copies per liter of wastewater detected by RT- qPCR (Fig 3). The average percent reads aligned to the SARS-CoV-2 genome from weekly sampling roughly corresponds to the genome copies/L in wastewater from the corresponding time period,
281 282 283 284 285 286 286 287	Percent reads aligned vs genome copies of SARS-CoV-2 Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364) were compared against the weekly average SC2 genome copies per liter of wastewater detected by RT- qPCR (Fig 3). The average percent reads aligned to the SARS-CoV-2 genome from weekly sampling roughly corresponds to the genome copies/L in wastewater from the corresponding time period, emphasizing the dependence of high quality SC2 genome amplicon sequencing on circulating viral load.
281 282 283 284 285 286 287 288	Percent reads aligned vs genome copies of SARS-CoV-2 Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364) were compared against the weekly average SC2 genome copies per liter of wastewater detected by RT- qPCR (Fig 3). The average percent reads aligned to the SARS-CoV-2 genome from weekly sampling roughly corresponds to the genome copies/L in wastewater from the corresponding time period, emphasizing the dependence of high quality SC2 genome amplicon sequencing on circulating viral load. The lowest percent reads aligned were observed during February and March 2022 when SARS-CoV-2
281 282 283 284 285 286 287 288 288 289	Percent reads aligned vs genome copies of SARS-CoV-2 Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364) were compared against the weekly average SC2 genome copies per liter of wastewater detected by RT- qPCR (Fig 3). The average percent reads aligned to the SARS-CoV-2 genome from weekly sampling roughly corresponds to the genome copies/L in wastewater from the corresponding time period, emphasizing the dependence of high quality SC2 genome amplicon sequencing on circulating viral load. The lowest percent reads aligned were observed during February and March 2022 when SARS-CoV-2 was relatively scarce, but percent reads aligned increased beginning in April, with the surge of the
281 282 283 284 285 286 287 288 288 289 290	Percent reads aligned vs genome copies of SARS-CoV-2 Weekly average percent reads aligned to the SC2 genome using both enrichment panels (n=364) were compared against the weekly average SC2 genome copies per liter of wastewater detected by RT- qPCR (Fig 3). The average percent reads aligned to the SARS-CoV-2 genome from weekly sampling roughly corresponds to the genome copies/L in wastewater from the corresponding time period, emphasizing the dependence of high quality SC2 genome amplicon sequencing on circulating viral load. The lowest percent reads aligned were observed during February and March 2022 when SARS-CoV-2 was relatively scarce, but percent reads aligned increased beginning in April, with the surge of the Omicron variants, through the end of the monitoring period for this study, June 2022.

291 Comprehensive QC metric analysis

292	To characterize sequencing performance, C-WAP outputs a comprehensive report with several
293	distinct quality metrics including the aforementioned percent reads aligned to the SC2 genome,
294	coverage depth of the sequencing reads at every genomic coordinate of the SC2 genome, read quality,
295	read counts for each primer pair of the amplicon panel, coverage depth over the entire breadth of the
296	SC2 genome, absolute counts of genomic coordinates with less than 10X coverage or no coverage,
297	scaled counts of genomic coordinates that with less than 10X coverage or no coverage, and variant
298	abundance estimation using Freyja, kallisto, and Kraken (Supplementary report 1, 2). The following
299	sections includes detailed results of the metrics considered by C-WAP for the samples discussed in the
300	study.
301	Coverage depth vs coverage breadth:
302	We compared sequencing depth versus breadth of the SC2 genome for both amplicon kits,
303	QIAseq DIRECT and NEB VSS. The ideal sequencing run would have the maximum sequencing depth
304	(greatest number of reads aligned) over the entire breadth (100%) of the genome, indicating even
305	coverage over all genomic coordinates. Across the time course of this study, the coverage depth versus
306	breadth for each amplicon kit used for each month of wastewater surveillance (Fig 4) improved as we
307	optimized our sample collection and sequencing methods, with values for the metric converged towards
308	the ideal in June compared to January. Comparison of the amplicon panels shows that the NEB VSS
309	panel has lower genome coverage when compared to the QIAseq DIRECT panel for January and
310	February, but by June the breadth versus depth for all sequencing runs are similar between amplicon
311	kits.
312	Genome coverage across ORF1ab, S, M, and N genes of SC2 genome:
313	Calculations of absolute and scaled coverage for each nucleotide site within all SC2 genes (5'

UTR, ORF1ab, S, ORF3a, E, M, ORF6, ORF7ab, ORF8, N, ORF10, 3'UTR) was extracted from the C-WAP

315 report. Genome coverage for four key genes, namely ORF1ab, S, M and N genes, was used to detect 316 characteristic mutations of the variants from January through June 2022 (Fig 5) during this study. Both 317 NEB VSS and QIAseq DIRECT enrichment panels had more under-covered (<10x) sites within the S gene 318 when compared to coverage of the remaining three key genes. 255 samples enriched by QIAseq DIRECT 319 showed under-coverage in the S gene, versus an average of 166 samples for the other three key genes, 320 while 109 samples enriched by NEB VSS showed S gene under-coverage, versus an average 92.3 321 samples? for the other three genes. An overall poor performance of QIAseg DIRECT on the M gene was 322 observed across all months of sampling, when compared to NEB VSS, with the average scaled M gene 323 under-coverage across all QIAseq DIRECT samples 117% greater than that of NEB. In contrast, the NEB 324 VSS amplicon panel was observed to have more under-covered sites on ORF1ab and N genes across all 325 months of sampling—78% and 13% greater average scaled under-coverage, respectively.

326 Concordant Correlation Coefficient

327 To further assess performance and agreement between the two amplicon panels and the 328 variant callers used in this study, we computed concordant correlation coefficients (CCC) to compare the 329 performance of the top two variant callers (9), Freyja and kallisto, using a subset of high-quality 330 sequenced samples, determined by having good QC metrics with uniform coverage across the genome 331 (Fig 6). The CCC was positive for each kit, though under 0.25 for each, indicating mild agreement 332 between the variant callers (Fig 6). The CCC between the variant callers was relatively higher for QIAseq 333 DIRECT samples (0.2113 as opposed to 0.0102 for NEB VSS) and had a 95% confidence interval that did 334 not span 0, indicating a statistically significant agreement. In contrast, the CCC for NEB VSS samples had 335 a 95% confidence interval spanning 0, indicating there is likely no relationship between the variant 336 detection calls by Freyja and kallisto. Accordingly, this suggests that for NEB VSS samples with GridION 337 sequencing, one variant caller may be a better choice than the other to produce the most accurate

results, while for QIAseq DIRECT samples with MiSeq sequencing, the choice of variant caller may be less
 important.

340 **Circulating variant estimation**:

341 During the sampling period, our surveillance system not only captured the major and minor 342 variants circulating within the community but also detected the emergence of new variants. We 343 combined the variant results from all 364 sequences from 182 samples, agnostic to the kit and 344 sequencing platform used, to observe the general trend of circulating variants using Freyja as its 345 database is updated more frequently. The MD wastewater samples clearly identified the emerging 346 variants of concern like BA.1, BA.2.12, BA.4.6 and BA.5 from January 2022 through June 2022 (Fig 7, 347 Supplementary Fig 1). Omicron BA.1 was the dominant circulating variant when the wastewater sampling began in January 2022. January 29th samples showed signs of emergence of BA.2, and 348 349 dominant detection of BA.2 was observed from March 30th, 2022. BA.2.12 was detected starting from 350 end of March 2022, followed by BA.4 and BA.5 in mid-May, and dominantly detected starting end of 351 May 2022. We also observed traces of BA.4.6 in mid to late June, agreeing with the onset of BA.4.6 in 352 clinical cases in Maryland.

353 Early detection of BA.2:

The BA.2 lineage was first detected in samples collected on January 29th, 2022, and again on January 31, 2022 with both the NEB VSS and QIAseq DIRECT enrichment panels. The first clinical reporting of the BA.2 lineage in the entire state of MD by the CDC was on January 27th, 2022 (variant data is not available per zip code). To verify the early detection of BA.2 in these wastewater samples, every mutation identified using both enrichment panels was examined for six days (January 27th– February 1st) surrounding the first purported appearance of BA.2 (Fig 8A). Detected mutations for each day were categorized based on their presence/absence in BA.1 and BA.2 lineage sequences. Mutations

361	shared between BA.1 and BA.2 in the characteristic mutation table generated by C-WAP were marked as
362	"BA.1 or BA.2" mutations. Identified mutations that are not present in BA.1 were categorized as
363	"Incompatible with BA.1" and mutations only present in BA.2 were categorized as "BA.2 diagnostic
364	mutations." All mutations detected were considered statistically significant (p-value < 0.05) and present
365	in at least 10 sequencing reads.
366	The prevalence of these three mutation categories on both enrichment panels on each of four
367	days in January and in March 2022, when BA.2 was well established, was visualized by showing the
368	frequency of each mutation and its place in the SARS-CoV-2 genome (Fig 8B). The landscape of relevant
369	mutations on both early BA.2-detection days (January 29 th and 31 st) is highly similar to the pattern of
370	mutation prevalence and detection in March, when BA.2 was consistently present in both wastewater
371	and clinical samples. BA.2 diagnostic mutations were detected with frequencies up to at least 0.5 in
372	some samples, while most detected BA.1-incompatible mutations were present with frequency of 0.25
373	or greater.
374	In contrast, the mutations detected on January 28 include no BA.2 diagnostic mutations and

BA.1-incompatible mutations are largely present in low frequency. This shows the presence and
frequency of BA.2 diagnostic mutations and the overall profile of mutations observed at the early
detection dates, January 29th and 31st, mimic that from a later sample, from March 30th, when BA.2 was
known to be present in the WWTP service area.

379 **Realtime submission of surveillance data:**

After the sequencing protocol was optimized and QC metrics were in place, we made an effort to quantify the minimum time from sample collection to sequence analysis and release. Composite grabs for the week of June 28th, 2022, were collected at 6 am from the treatment plant and the time to process these samples was recorded. Total nucleic acid extraction, cDNA synthesis, amplification using

384 NEB VSS enrichment panel, and loading of the libraries on to Oxford Nanopore GridION took 30hrs. After 385 16hrs, we had collected sufficient sequence data that passed QC to detect all the characteristic and 386 diagnostic mutations for BA.5. Data analysis using C-WAP, upload of this data to NCBI, and display on the 387 dashboard took 11 hrs. The total turnaround time from sample collection to dashboard display was 388 57hrs. 389 Discussion 390 Six months of wastewater surveillance, made possible through the partnership with a 391 wastewater treatment plant in Maryland, detected new variants as they emerged along with major and 392 minor variants circulating in the community. From a clinical perspective, this level of resolution of 393 community disease dynamics could underpin traditionally monitored clinical testing and help public 394 health officials to serve communities more efficiently. A wastewater surveillance system fills data gaps 395 for areas where clinical testing and surveillance may be limited, including underserved communities 396 with limited access to testing sites. 397 The laboratory and bioinformatic methods employed in this study confidently detected multiple 398 circulating SARS-CoV-2 (SC2) variants in wastewater samples using amplicon-based targeted enrichment 399 panels. Several enrichment panel kits were evaluated, but only two, the QIAseq DIRECT and NEB VSS 400 panels were pursued as the best options for wastewater samples. 401 The viral load in wastewater, when compared to the clinical cases, indicated a low rate of clinical 402 testing as the pandemic began to wane (Fig 2). In other words, there were higher levels of SC2 in the 403 community, based on wastewater analysis, than were being estimated based on reports from clinical 404 testing. This is perhaps because at-home test kits became widely available within the community around 405 the same time as this study commenced. From wastewater data, it is evident that clinical testing did not 406 fully capture the wave of infections during early April to June 2022 (Fig 2). A limit of detection with

genome copies/L to the SC2 hits was not established and so all samples were sequenced regardless of
RT-qPCR result (22). Having strict QC measure in place helped us to overcome this lack of a robust RTqPCR LOD threshold and eliminate some poorly performing samples attributed to the lower genome
copies/L.

A main goal of wastewater surveillance is to track emerging and circulating variants at a community level and hopefully provide an early warning signal of emerging and increasing infections without the need for community clinical information. For example, we detected BA.2 ahead of the clinical findings for the state. It is important to note that the variant calls are published only at the state level by CDC, not at the ZIP code level. Here we detected BA.2 at the community level covering two ZIP codes 14 days ahead of BA.2 variant calls published by CDC at the state level for Maryland. This emphasizes an ability of community level surveillance using wastewater: enabling a more focused public

418 health local response during a pandemic.

419 In SC2 variants, mutations across the S-gene play a crucial role in variant calling. Research is 420 ongoing to elucidate the mechanisms involved but the mutations may boost infectivity and 421 transmissibility through increased spike density, enhanced cleavage and host cell uptake, and increased 422 viral load and ability to evade host immune responses (23). Mutations may also interfere with laboratory 423 testing and complicate epidemiological monitoring by interfering with detection in sequence-based 424 tests. If a mutation occurs in the part of the viral genome assessed by a PCR test, the sample may result 425 in gene "dropout." We observed a significant drop in coverage of the S gene with the NEB VSS panel on 426 the week of May 11. For this same week, RT-qPCR of these samples had 90,587 genome copies/L 427 indicating a high SC2 viral load in the community (the range of genome copies for the duration of this 428 study was from 350 genome copies/L to 99840 genome copies/L). The significant drop in S gene 429 coverage raised concerns and the vendor was contacted and spike-in to the primer pool 1 was obtained 430 to overcome the dropout due to the rise of BA.5 sub variants. When we repeated the amplification and

431 sequencing of samples from the week of May 11 using the primer spike-in (NEB VSS), we observed 432 improved coverage on the S gene because of the three characteristic mutations (S:S371F, S:T376A, 433 S:D405N) detected with the spike-in that were not detected with the original primer panel. 434 A diagnostic mutation of BA.5 in the M gene (M:D3N) was first detected the week of May 11 435 with QIAseq DIRECT enrichment panel. This same mutation was not detected until the week of June 1 436 using NEB VSS enrichment panel. A spike-in for the QIAseg DIRECT enrichment panel was introduced 437 from the week of June 13. The spike-in primers in the QIAseq DIRECT panel had a slightly higher 438 concentration of primers compared to its original panel across this region (23082-23144 bp). While 439 there was not a full dropout in this region (23082-23144 bp), the observed coverage was lower, and the 440 concentration of the primers (QIAseq_170_RIGHT, QIAseq_172_LEFT, and QIAseq170-2_RIGHT) were 441 increased to provide more uniform coverage within that gene. Since mutations may affect detection, 442 treatment, and prevention, it is important to identify strains correctly to direct public health 443 containment strategies (5). To address this type of limitation, there are studies that incorporate targeted 444 sequencing of only variable regions of interest in the genome, particularly those regions that contain 445 mutations unique to specific variants of concern (5). In addition, there are studies that apply PCR 446 amplifying, cloning, and sequencing a 1.52kb region of the spike protein gene to confirm the linkage of 447 mutations of interest to understand all the circulating variants in a complex sample (24). While these 448 approaches provide valuable information on a very targeted genomic area where mutations are known 449 to occur, mutations at other genomic coordinates, which might be indicative of emergent variants and 450 variants, will not be obtained.

In practice, when a diagnostic or surveillance test is based on targeted amplification, for it to be able to detect variations in the genome of pathogens, it is necessary to regularly update the primer pairs and/or alter the target regions used in the detection systems or use several target genes of the infectious agent in the same test reaction to minimize the risk of false negative results (5). Both

455 enrichment panels evaluated in this study consistently updated the primer pairs for the detection of 456 circulating variants. In an ARTIC primer approach where entire primer versions are updated, the 457 emergence of new variants renders any remaining primers obsolete (25, 26). This stands in contrast to 458 the spike-in approach, where the spike-in is introduced to the original pools, minimizing the 459 regeneration of old primers and revitalizing their performance. Many enrichment panels contain 460 degenerate primer designs of polymorphic regions of the genome to allow more robust amplification of 461 variable strains. Also, strategically designed primer pairs for consistent coverage are essential for highly 462 evolving genomes like SC2 (5). Keeping the challenges of uniform coverage within the targeted site, 463 primer binding efficiency, and adaptation to several sequencing approaches in mind, choosing a suitable 464 target enrichment panel and pairing it with the suitable library preparation kit based on the sequencing 465 platform may play a critical role in identifying the circulating and emerging variants.

466 When we assessed genome coverage metrics for four key genes (ORF1ab, S, M and N genes), 467 both QIAseg DIRECT enrichment panel and NEB VSS enrichment panel had substantial under-covered 468 regions on the S gene when compared to the other three genes. In the NEB VSS SARS-CoV-2 enrichment 469 panel, there are 10 primer pairs targeting the S gene (genome coordinates:21563-25384) with an 470 overlapping primer pair included to enable detection of BA.5 specific mutations. The S gene is the most 471 mutation-prone region of SC2 genome, which means that primer binding sites for this gene can play a 472 major role in variant calling performance on a mixed sample like wastewater. For the M gene, the 473 QIAseq DIRECT enrichment panel had lower coverage across all months when compared to NEB VSS 474 enrichment panel (Fig 5). Two characteristic mutations within the M gene used to assess all Omicron sub 475 variants correspond to primer binding regions in the QIAseq DIRECT enrichment panel, while neither 476 mutation is in a primer binding region for NEB VSS. The QIAseq DIRECT enrichment panel has more 477 amplicons with more primer pairs (222 primer pairs total, whereas NEB VSS panel has 74 primer pairs) 478 and is more suitable for short read sequencing (~250bp amplicon length) which results in high coverage

across the genome. But there is a greater chance of mutations occurring in a primer binding site,
especially for rapidly evolving genes, such as the S gene. The NEB VSS primer panel somewhat mitigates
this with longer amplicon length (~560bp) and fewer primer pairs. Continuous evaluation of current and
emerging target enrichment panels is essential to accurately detect existing and evolving SC2 variants
from wastewater.

During the development of C-WAP, a critical performance assessment of various variant callers on *in silico* reads of mixed variants revealed that Freyja was the most suitable variant caller on short read data and kallisto was the most suitable variant caller for the long read data (9). The concordant coefficient analysis on our real-world data agreed with those previous findings (Fig 6) However, to solidify these conclusions, further investigations are warranted, particularly with a larger sample size. Additionally, considering the evolving nature of viruses, future studies should explore the impact of different amplification kits on variant calling accuracy.

491 We tested the feasibility of the real time submission of data to support the public health 492 response. Real time submission and publication to the dashboard within 57 hours was possible because 493 of real-time long read sequencing through Oxford Nanopore GridION. After just 16 hrs of sequencing, 494 there was enough accumulated sequencing depth data that passed QC to provide high confidence in the 495 accuracy of variant calling. Even though the run time in GridION was chosen to be 72hrs, most of the 496 data were collected in the initial 20hrs after sequencing started. However, to ensure high quality data, 497 we multiplexed only 9 samples per flow cell on GridION, compared to 28-32 possible samples on 498 Illumina MiSeq. The Illumina MiSeq, despite its inherent speed limitations, presents promising prospects 499 for near-real-time applications when Read1 data is being used. While just the Read1 data can 500 successfully pass all quality control (QC) metrics, there is a subsequent delay of up to 24 hours for 501 uploading the sequence data from a paired-end run, which might be advantageous for maximizing 502 quality scores. It is important to understand the complexity associated with multiplexing samples per

503 flow cell, a factor that may necessitate adjustments based on the viral load. Our team has established 504 best practices for the efficient collection, organization and surveillance of sequence data (21). Analyzing 505 the turnaround time from sample collection to NCBI data release revealed a median duration of 506 approximately 28 days for the samples in this study. However, this exercise has illuminated the potential 507 for real-time data submission, enabling immediate surveillance insights. Regardless of the sequencing 508 technology, near real time data submission is possible through wastewater surveillance which will 509 support community level decision making easier during pandemic. Incorporation of automated liquid 510 handling robots could further reduce time from sample receipt to data publication. 511 Due to the dynamic and swiftly evolving nature of SARS-CoV-2, our dedication to real-time 512 dashboard updates and the dissemination of optimized protocols to the wastewater surveillance 513 community, this study has some limitations. One limitation was the inability to delve into the genuine 514 distinctions in raw wastewater and composites beyond a one-week sample analysis period where we explored both raw wastewater grabs (February 23rd to February 28th) and composite grabs (February 515 516 23rd to February 28th). We needed to investigate the feasibility of weekly sample pooling as a strategy (February 28th, 2022, and onwards) to reduce the processing workload in our laboratory, and when we 517 518 did not find any differences in the viral load and other QC metrics when the sequences, regardless of 519 enrichment panel, were analyzed from that week, we proceeded with weekly sample pooling. 520 Additionally, we were constrained in exploring the potential benefits of multiplexing varying sample 521 quantities on GridION flow cells to comprehend sequencing depth. This study is also limited by not 522 including an evaluation of other commercially available enrichment panels, such as ARTIC V4 or Resende 523 (26, 27). Moreover, the study was hindered in its capacity to investigate spike-in studies with known 524 concentration of the virus in various matrices, which are essential for establishing a true limit of 525 detection.

526	The two amplicon panel kits demonstrated robust efficacy in detecting both circulating and
527	emerging variants in wastewater samples. The two panels used in this study underwent sequencing on
528	two distinct platforms, and to ensure accurate assessment, we established customized quality control
529	(QC) metrics using C-WAP. Regarding variant calling, both enrichment panels successfully detected the
530	presence of BA.2 on January 29 th , 2022, samples and consistently detected other circulating variants
531	throughout the study duration. The comprehensive analysis employed in this study emphasizes the
532	importance of evaluating the performance of any enrichment panel in conjunction with the chosen
533	sequencing technology.
534	Conclusion

535 We supported the public health response effectively during the pandemic by constant method

optimization, updates to the wet lab protocol, updates to the databases for the variant calling,

537 comprehensive analysis, pairing up the enrichment panel with suitable sequencing technology,

538 appropriate variant callers used throughout the surveillance, and the efficient updates of a dashboard.

539 Finally, as seen here, our findings highlight the value of extensive data analysis metrics, method

540 optimization, and a near-real-time public health response. These insights can serve as valuable

541 considerations for decision-making in the establishment of new surveillance initiatives, especially those

542 involving mixed samples and complex sample types such as wastewater. In essence, this study provides

543 a blueprint for thoughtful consideration of various metrics when conducting surveillance using target

enrichment panels, offering valuable lessons that can inform the development of future surveillance

545 studies.

546 References

5471.Karthikeyan S, Levy JI, De Hoff P, Humphrey G, Birmingham A, Jepsen K, et al. Wastewater548sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature. 2022;609(7925):101-8.

549 Ahmed W, Bertsch PM, Bibby K, Haramoto E, Hewitt J, Huygens F, et al. Decay of SARS-CoV-2 2. 550 and surrogate murine hepatitis virus RNA in untreated wastewater to inform application in wastewater-551 based epidemiology. Environ Res. 2020;191:110092. 552 3. Achak M, Alaoui Bakri S, Chhiti Y, M'Hamdi Alaoui FE, Barka N, Boumya W. SARS-CoV-2 in 553 hospital wastewater during outbreak of COVID-19: A review on detection, survival and disinfection 554 technologies. Sci Total Environ. 2021;761:143192. 555 Fontenele RS, Kraberger S, Hadfield J, Driver EM, Bowes D, Holland LA, et al. High-throughput 4. 556 sequencing of SARS-CoV-2 in wastewater provides insights into circulating variants. Water Res. 557 2021;205:117710. 558 Smyth DS, Trujillo M, Gregory DA, Cheung K, Gao A, Graham M, et al. Tracking cryptic SARS-CoV-5. 559 2 lineages detected in NYC wastewater. Nat Commun. 2022;13(1):635. 560 Farkas K, Hillary LS, Malham SK, McDonald JE, Jones DL. Wastewater and public health: the 6. 561 potential of wastewater surveillance for monitoring COVID-19. Curr Opin Environ Sci Health. 2020;17:14-562 20. 563 7. Aguiar-Oliveira ML, Campos A, A RM, Rigotto C, Sotero-Martins A, Teixeira PFP, et al. 564 Wastewater-Based Epidemiology (WBE) and Viral Detection in Polluted Surface Water: A Valuable Tool for COVID-19 Surveillance-A Brief Review. Int J Environ Res Public Health. 2020;17(24). 565 566 8. Hamouda M, Mustafa F, Maraqa M, Rizvi T, Aly Hassan A. Wastewater surveillance for SARS-567 CoV-2: Lessons learnt from recent studies to define future applications. Sci Total Environ. 568 2021;759:143493. 569 Kayikcioglu T, Amirzadegan J, Rand H, Tesfaldet B, Timme RE, Pettengill JB. Performance of 9. 570 methods for SARS-CoV-2 variant detection and abundance estimation within mixed population samples. 571 PeerJ. 2023;11:e14596. 572 Wang Y, Hu X, Yang L, Chen C, Cheng H, Hu H, et al. Application of High-Throughput Sequencing 10. 573 Technology in the Pathogen Identification of Diverse Infectious Diseases in Nephrology Departments. 574 Diagnostics (Basel). 2022;12(9). 575 Suminda GGD, Bhandari S, Won Y, Goutam U, Kanth Pulicherla K, Son YO, et al. High-throughput 11. 576 sequencing technologies in the detection of livestock pathogens, diagnosis, and zoonotic surveillance. 577 Comput Struct Biotechnol J. 2022;20:5378-92. 578 12. Ko KKK, Chng KR, Nagarajan N. Metagenomics-enabled microbial surveillance. Nat Microbiol. 579 2022;7(4):486-96. 580 Iwu-Jaja C, Ndlovu NL, Rachida S, Yousif M, Taukobong S, Macheke M, et al. The role of 13. 581 wastewater-based epidemiology for SARS-CoV-2 in developing countries: Cumulative evidence from 582 South Africa supports sentinel site surveillance to guide public health decision-making. Sci Total Environ. 583 2023;903:165817. 584 14. GenomeTrakr-protocols-wastewater [Available from: https://www.protocols.io/file-585 manager/682C9E830C0A11EC806D0A58A9FEAC02. 586 15. Freed NE, Vlkova M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing 587 of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biol Methods 588 Protoc. 2020;5(1):bpaa014. 589 Swift BioSciences. "NEW- Swift Normalase™ Amplicon SARS-CoV-2 Panels." [Available from: 16. 590 https://swiftbiosci.com/swift-normalase-amplicon-sars-cov-2-panels-3/. 591 VarSkip Multiplex PCR Designs for SARS-CoV-2 Sequencing. 2021. Reprint, New England Biolabs 17. 592 Inc., 2021 [Available from: https://github.com/nebiolabs/VarSkip. 593 18. The Pango nomenclature is being used by researchers and public health agencies worldwide to 594 track the transmission and spread of SARS-CoV-2, including variants of concern. [Available from: 595 https://cov-lineages.org/

596 Cui Y, Peng L, Hu Y, Lai HJ. Assessing the Reproducibility of Microbiome Measurements Based on 19. 597 Concordance Correlation Coefficients. J R Stat Soc Ser C Appl Stat. 2021;70(4):1027-48. 598 20. Palarea-Albaladejo J M-FJ. zCompositions- R package for multivariate imputation of left-599 censored data under a compositional approach. Chemometrics and Intelligent Laboratory Systems. 600 2015;143:85-96. 601 21. Timme RE, Woods J, Jones JL, Calci KR, Rodriguez R, Barnes C, et al. SARS-CoV-2 wastewater 602 variant surveillance: pandemic response leveraging FDA's GenomeTrakr network. medRxiv. 603 2024:2024.01.10.24301101. 604 Bivins A, Kaya D, Bibby K, Simpson SL, Bustin SA, Shanks OC, et al. Variability in RT-qPCR assay 22. 605 parameters indicates unreliable SARS-CoV-2 RNA quantification for wastewater surveillance. Water Res. 606 2021;203:117516. 607 Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, et al. Emerging SARS-CoV-2 23. 608 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines (Basel). 2021;9(10). 609 24. Iwamoto R, Yamaguchi K, Katayama K, Ando H, Setsukinai KI, Kobayashi H, et al. Identification of 610 SARS-CoV-2 variants in wastewater using targeted amplicon sequencing during a low COVID-19 611 prevalence period in Japan. Sci Total Environ. 2023;887:163706. ARTIC primer revamping [Available from: https://community.artic.network/c/laboratory/6. 612 25. 613 26. Tyson JR, James P, Stoddart D, Sparks N, Wickenhagen A, Hall G, et al. Improvements to the 614 ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv. 2020. 615 Paola Cristina Resende FCM, Sunando Roy, Luciana Appolinario, Allison Fabri, Joilson Xavier, 27. 616 Kathryn Harris, Aline Rocha Matos, Braulia Caetano, Maria Orgeswalska, Milene Miranda, Cristiana 617 Garcia, André Abreu, Rachel Williams, Judith Breuer, Marilda M Sigueira. SARS-CoV-2 Genomes 618 Recovered by Long Amplicon Tiling Multiplex Approach Using Nanopore Sequencing and Applicable to 619 Other Sequencing Platform. BioRXIV. 2020.

620

621 Acknowledgements

- 622 We gratefully acknowledge the wastewater treatment plant for collecting samples for this study and
- 623 sharing it with us. We acknowledge Dr. Leena Malayil and Dr. Amy Sapkota, School of Public Health,
- 624 University of Maryland for introducing us to the WWTP for sample collection. We acknowledge
- 625 CovidTrakr working groups at the Center for Food Safety and Applied Nutrition (CFSAN) for discussion
- that facilitated this manuscript. We also acknowledge the support of CFSAN high performance
- 627 computing engineers G. Engelbach, J. Payne, K. Konganti, and M. Hammond. We acknowledge all data
- 628 contributors for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on
- 629 which this research is partly based.

631 Author Contributions

632	PR performed sample collection, lab experiments, data interpretations and wrote and edited the
633	manuscript. TK developed C-WAP and performed data analysis and interpretation. PR, AW, CG and MH
634	conceived and designed the study and performed laboratory experiments. KJ performed lab
635	experiments and data interpretation. CB, TP, MB, ST and RT developed the dashboard. EB retrieved
636	samples from WWTP. BT performed concordant correlation coefficient analysis. JA, DE, JP and HR
637	performed data analysis. All authors reviewed and edited the manuscript and approved the final
638	version.
639	Funding
640	This project was supported in part by funding from the American Rescue Plan Act of 2021. Jasmine
641	Amirzadegan, Candace Hope Bias, Kathryn Judy, and Tammy Walsky's participation was supported by an
642	appointment to the Research Participation Program at the U.S. Food and Drug Administration
643	administered by the Oak Ridge Institute for Science and Education through an interagency agreement
644	between the U.S. Department of Energy and the U.S. Food and Drug Administration. Tunc Kayikcioglu
645	and Dietrich EppSchmidt received financial support from Joint Institute for Food Safety and Applied
646	Nutrition (JIFSAN), University of Maryland as part of financial assistance award U01FD001418 funded by
647	the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS).
648	The funders had no role in study design, data collection and analysis, decision to publish, or preparation
649	of the manuscript.
650	
651	Table 1: QC metrics monitored for data submission and further analysis.

652 Schematic Fig1 : Weekly collection and processing of composite samples: From February 23rd through

June 30, 2022, daily composite samples were pooled into a single sample of two biological replicates per

week. Each biological replicate was then split into three 40mL technical replicates, resulting in six
samples per week that was taken into further processing.

Figure 1: Flowchart of wastewater processing and analysis workflow: Wastewater samples collected

from the treatment plant were pooled by week and the total nucleic acid (TNA) was extracted using

658 Promega Enviro TNA kit. Genomic DNA was digested with ezDNase prior to cDNA synthesis using

659 Superscript IV Reverse Transcriptase. The cDNA was amplified using either NEBNext VarSkip Short (VSS)

660 primers for long-read (~550bp) sequencing on the Oxford Nanopore Technologies GridION or QIAseq

661 DIRECT (QIAseq) primers for short-read (~250bp) sequencing on the Illumina MiSeq. All sequences were

662 processed through the CFSAN Wastewater Analysis Pipeline, producing a report that included QC

663 metrics as well as relative abundance of variants. Sequences that pass QC are submitted to NCBI and the

variant calls were published in the FDA dashboard.

665 Figure 2: SARS-CoV-2 viral load and relationship to clinical cases: The relationship of wastewater-based

surveillance burden estimations and actual clinical reporting, with clinical data plotted against the viral

genome copies/L, over time. The rolling 7-day average of new clinical SARS-CoV-2 cases (black) in the

sewer shed graphed alongside the viral load over time (blue), calculated from RT-qPCR on raw

669 wastewater and 24h composite samples taken from the wastewater treatment plant. Number of cases is

670 indicated on the right-hand axis, while genome copies/L is marked on the left.

Figure 3: Percentage of aligned reads vs. wastewater viral load : Weekly average percent reads aligned

to the SC2 genome (black) and the weekly average SC2 viral load (gc/L) detected by RT-qPCR from

673 wastewater (orange). Sequencing runs/data from both enrichment panels (NEB VSS and QIAseq DIRECT,

n=364) included in the averaging to calculate the weekly percent reads aligned were quality filtered to <

675 20% sites with 0x coverage and < 40% sites covered <10x after alignment.

676 Figure 4: Coverage depth vs coverage breadth: Sequencing depth versus breadth of the SARS-CoV-2 677 genome covered for each amplicon kit and every month of wastewater surveillance. Any point along a 678 given line indicates the percentage (breadth, y-axis) of the SARS-CoV-2 genome covered to the 679 corresponding sequence depth (x-axis) for that single sample. The green bar on the first panel of January 680 2022, shows an ideal sequencing run with maximum depth covering the entire genome. Each line 681 indicates one sequenced sample that resulted in <20% sites along the genome covered 0x and <40% 682 sites covered <10x after alignment. 683 Figure 5: Genome coverage across ORF1ab, S, M, and N genes of SC2 genome: Genome coverage by 684 amplicon kit for key genes used to detect SARS-CoV-2 variants from January through June 2022. The 685 averaged number of under-covered (fewer than 10 quality-filtered and trimmed reads aligned) for each 686 gene and amplicon kit over time is indicated in red, with worse coverage (poorer sequencing 687 performance) in lighter colors. 688 Figure 6: Concordant Correlation Coefficient (CCC) analysis: concordant correlation coefficient analysis 689 on the variant calling performance of Freyja and kallisto on eleven samples between May and June 2022 690 sequenced with both NEB VarSkip Short and QIAseq DIRECT primers. A CCC of +1 indicates perfect agreement, -1 indicates perfect disagreement, and 0 indicates no agreement. 691 692 Figure 7: Proportional abundance of SARS-CoV-2 variants detected over time: Proportional abundance 693 of SARS-CoV-2 variants detected over time, as identified by the Freyja variant caller on sequence data 694 from both the enrichment panels (NEB VSS and QIAseq DIRECT, n=364). Variants always detected in a 695 proportion of less than 1% were grouped together as "Others <1%". Figure 8: Verification of the BA.2 variant detection in wastewater on January 29th, 2022, using both the 696 697 enrichment panel (NEB VSS and QIAseq DIRECT): 8A. Proportional abundance of SARS-CoV-2 variants by

698 day, January 27th – February 1st 2022. 8b. Frequency of BA.1 and BA.2 –characteristic mutations over

- 699 four dates. Mutations typically incompatible with BA.1 (teal), characteristic for BA.1 or BA.2 (purple),
- and diagnostic for BA.2 (green, in a highlighted box) are shown at their location in the SARS-CoV-2
- genome. All depicted mutations are significant (p-value < 0.05), but smaller circles indicate lower p-
- values. BA.2 was detected in the bottom three date panels.
- 703 Supplementary table1: Sample collection and pooling strategies employed in this study.
- 704 Supplementary table 2: Characteristic mutation table by C-WAP.
- Supplementary table 3:Rolling 7 day average of new cases for zip codes monitored in this study along
- 706 with the wastewater viral load (gc/L).
- Supplementary Figure 1: SC2 population trend by sampling date using both the enrichment panel and
- 708 Freyja as the variant caller.
- 709 Supplementary reports: Example reports of the comprehensive analysis produced by C-WAP.









gene length by scaled sites, poorly Average





ORF1ab

Number of poorly covered sites, scaled













SC-2 variants Omicron: BA.1 Omicron: BA.2 Omicron: BA.2.12 Omicron: BA.3 Omicron: BA.4 Omicron: BA.4.6 Omicron: BA.5 Other B.* Other B.1.* Other B.1.* Omicron: B.1.1.529 A Sublineages X*: Recombinants Others < 1%







